v3.25.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY - EUR (€)
€ in Thousands
Total
Kreos OCABSA
Heights convertible notes
Kreos & Claret financing
Other equity agreements
SHARE CAPITAL
SHARE CAPITAL
Kreos OCABSA
SHARE CAPITAL
Heights convertible notes
SHARE CAPITAL
Kreos & Claret financing
PREMIUMS RELATED TO SHARE CAPITAL
PREMIUMS RELATED TO SHARE CAPITAL
Kreos OCABSA
PREMIUMS RELATED TO SHARE CAPITAL
Heights convertible notes
PREMIUMS RELATED TO SHARE CAPITAL
Kreos & Claret financing
PREMIUMS RELATED TO SHARE CAPITAL
Other equity agreements
TRANSLATION RESERVE
RETAINED EARNINGS
RETAINED EARNINGS
Kreos OCABSA
NET LOSS FOR THE YEAR
Number of shares issued at beginning of period (in shares) at Dec. 31, 2023 62,928,818                                  
Reconciliation of number of shares outstanding [abstract]                                    
Exercises of share warrants (in shares) 4,000                                  
Issue of free shares (in shares) 361,835                                  
Number of shares issued at end of period (in shares) at Sep. 30, 2024 63,294,653                                  
Equity at beginning of period at Dec. 31, 2023 € 196,009         € 629       € 478,218         € 112 € (135,210)   € (147,740)
Changes in equity [abstract]                                    
Net loss for the period (136,864)                                 (136,864)
Other comprehensive income (loss) 161                           104 56    
Total comprehensive income (loss) for the period (136,704)                           104 56   (136,864)
Appropriation of prior period net loss 0                             (147,740)   147,740
Transaction costs related to capital increase 446                 446                
Issue of share warrants 200                 200                
Exercise of Kreos/Claret and other share warrants 45                 45                
Issue of free shares 0         4       (4)                
Shares based compensation expense 15,767                             15,767    
Transactions on treasury shares 120                             120    
Equity at end of period at Sep. 30, 2024 € 75,883         633       478,905         217 (267,007)   (136,864)
Number of shares issued at beginning of period (in shares) at Dec. 31, 2024 63,347,837                                  
Reconciliation of number of shares outstanding [abstract]                                    
Capital increase from issuance of ordinary shares (in shares) 11,679,400                                  
Exercises of share warrants (in shares)       525,913 24,246                          
Conversion of convertible instruments (in shares)   785,389 920,377                              
Issue of free shares (in shares) 546,905                                  
Number of shares issued at end of period (in shares) at Sep. 30, 2025 77,830,067                                  
Equity at beginning of period at Dec. 31, 2024 € 40,584         633       478,905         (75) (262,637)   (176,242)
Changes in equity [abstract]                                    
Net loss for the period (254,142)                                 (254,142)
Other comprehensive income (loss) 858                           818 40    
Total comprehensive income (loss) for the period (253,284)                           818 40   (254,142)
Appropriation of prior period net loss 0                             (176,242)   176,242
Capital increase from issuance of ordinary shares 637,462         117       637,345                
Transaction costs related to capital increase (40,264)                 (40,264)                
Issue of share warrants 300                 300                
Exercise of Kreos/Claret and other share warrants       € 33,768 € 193       € 5       € 33,763 € 193        
Conversion of Kreos OCABSA and heights notes   € 16,062 € 53,921       € 8 € 9     € 15,380 € 53,912         € 673  
Issue of free shares 0         5       (5)                
Shares based compensation expense 22,497                             22,497    
Equity at end of period at Sep. 30, 2025 € 511,238         € 778       € 1,179,528         € 743 € (415,669)   € (254,142)